# Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)

> **NCT03324360** · PHASE1 · RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 276 (estimated)

## Conditions studied

- Brain Metastases

## Interventions

- **DRUG:** Hyperpolarized 13C-Pyruvate

## Key facts

- **NCT ID:** NCT03324360
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-12-06
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03324360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03324360, "Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03324360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*